Literature DB >> 23180444

Anuria and abdominal pain induced by ceftriaxone-associated ureterolithiasis in adults.

Zhao-Lun Li1, Hong-Liang Li, Hai-Wen Chen, He-Cheng Li, Peng Zhang, Zi-Ming Wang, Tie Chong.   

Abstract

Ceftriaxone is known to cause biliary pseudolithiasis and, rarely, nephrolithiasis mainly in children. However, we reported the development of bilateral distal ureteral ceftriaxone-associated lithiasis in 7 adults, which suggests that the risk of ureterolithiasis impaction should be considered when treating patients with ceftriaxone, even in adults. To avoid strengthening greater renal damage, ureteroscopic insertion of double J stents may be an alternative management for patients with ureteral ceftriaxone-associated lithiasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180444     DOI: 10.1007/s11255-012-0330-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  14 in total

Review 1.  Pediatric ceftriaxone nephrolithiasis.

Authors:  Patricio C Gargollo; Carol E Barnewolt; David A Diamond
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

2.  Ceftriaxone associated nephrolithiasis: a prospective study in 284 children.

Authors:  Masoumeh Mohkam; Abdollah Karimi; Atoosa Gharib; Hamid Daneshmand; Alireza Khatami; Nozar Ghojevand; Mostafa Sharifian
Journal:  Pediatr Nephrol       Date:  2007-01-17       Impact factor: 3.714

3.  Reversible ceftriaxone-associated biliary pseudolithiasis in children.

Authors:  U B Schaad; J Wedgwood-Krucko; H Tschaeppeler
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

4.  Increased urinary calcium excretion caused by ceftriaxone: possible association with urolithiasis.

Authors:  Takahisa Kimata; Kazunari Kaneko; Masaya Takahashi; Masato Hirabayashi; Tomohiko Shimo; Minoru Kino
Journal:  Pediatr Nephrol       Date:  2011-10-27       Impact factor: 3.714

5.  Ceftriaxone: renal and biliary excretion and effect on the colon microflora.

Authors:  A Arvidsson; G Alván; B Angelin; O Borgå; C E Nord
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

6.  Ceftriaxone-associated biliary pseudolithiasis in children.

Authors:  Betül Biner; Naci Oner; Coşkun Celtik; Musa Bostancioğlu; Nermin Tunçbilek; Ahmet Güzel; Serap Karasalihoğlu
Journal:  J Clin Ultrasound       Date:  2006-06       Impact factor: 0.910

7.  Ceftriaxone crystallization and its potential role in kidney stone formation.

Authors:  Somchai Chutipongtanate; Visith Thongboonkerd
Journal:  Biochem Biophys Res Commun       Date:  2011-02-15       Impact factor: 3.575

8.  Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child.

Authors:  Jeffrey S Prince; Melvin O Senac
Journal:  Pediatr Radiol       Date:  2003-06-26

9.  Concentrative biliary secretion of ceftriaxone. Inhibition of lipid secretion and precipitation of calcium ceftriaxone in bile.

Authors:  Y Xia; K J Lambert; C D Schteingart; J J GU; A F Hofmann
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

10.  Gallbladder and urinary tract precipitations associated with ceftriaxone therapy in children: a prospective study.

Authors:  Ceyda Acun; L Oktay Erdem; Ayhan Söğüt; C Zuhal Erdem; Nazan Tomaç; Sadi Gündoğdu; Serafettin Cavuldak
Journal:  Ann Trop Paediatr       Date:  2004-03
View more
  3 in total

Review 1.  Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review.

Authors:  Yifan Zhang; Benxiang Ning; Huaijun Zhu; Xiaoming Cong; Leqing Zhou; Qiang Wang; Liming Zhang; Xizhao Sun
Journal:  Int Urol Nephrol       Date:  2016-04-28       Impact factor: 2.370

2.  Cefazolin sodium pentahydrate cause urolithiasis: a case report and literature review.

Authors:  Fujun Wang; Wen Nie; Zongjun Wang; Sujian Tian; Junqiang Dong
Journal:  J Surg Case Rep       Date:  2022-04-11

3.  Progressive Pseudolithiasis Associated with the Intravenous Administration of Ceftriaxone in Patients with Central Nervous System Infections.

Authors:  Setsuki Tsukagoshi; Kunihiko Ishizawa; Kimitoshi Hirayanagi; Shun Nagamine; Kouki Makioka; Yukio Fujita; Yoshio Ikeda
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.